Following a third quarter print and clinical update from Aurinia Pharmaceuticals (NASDAQ:AUPH) on its pivotal study in lupus nephritis (LN), Canaccord analyst Neil Maruoka continues to be largely bullish on this biotech player. The company's LN asset voclosporin between strong efficacy and a standout safety profile could attract some global attention for a partnering opportunity that has secured an eager bull in Maruoka.
More recent articles about Aurinia:
- Aurinia Pharmaceuticals Inc (AUPH) to Enter NASDAQ Biotech Index
- Analyst Neil Maruoka Bullish on Aurinia Pharmaceuticals Inc (AUPH) on Back of Attractive Worldwide Partnering Potential in Competitive LN Landscape
- H.C. Wainwright Likes Aurinia Pharmaceuticals' Opportunity at Hand in the Lupus Nephritis Market
- This Bull Sees Meaningful Market Potential for Aurinia Pharmaceuticals Inc (AUPH) Drug Voclosporin in Lupus Nephritis